Technology
Health
Pharmaceutical

Spero Therapeutics

$13.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-1.06%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SPRO and other stocks, options, ETFs, and crypto commission-free!

About

Spero Therapeutics, Inc. Common Stock, also called Spero Therapeutics, is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Read More Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Employees
41
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
227.98M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
90.66K
High Today
$13.49
Low Today
$13.10
Open Price
$13.35
Volume
41.29K
52 Week High
$19.00
52 Week Low
$5.52

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2017 IPO
US

News

Yahoo FinanceMar 15

Will Spero Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Spero Therapeutics. As of late, it has definitely been a great time to be an investor in Spero Therapeutics, Inc. SPRO. The stock has moved higher by 3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider SPRO’s recent earnings e...

10
Simply Wall StFeb 28

What Type Of Shareholder Owns Spero Therapeutics, Inc.’s (NASDAQ:SPRO)?

A look at the shareholders of Spero Therapeutics, Inc. (NASDAQ:SPRO) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Companies that have been privatized tend to have low insider ownership. Spero Therapeutics is a smaller company with a market capitalization of US$210m, so it may still be flying under the radar of many institutional investors. Taking a look at our data on the ownership groups...

9

Earnings

Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Available Mar 14, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.